Alleviation of extrapyramidal side effects upon switching from risperidone to paliperidone

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F11%3A00060845" target="_blank" >RIV/00216224:14740/11:00060845 - isvavai.cz</a>
Result on the web
<a href="http://www.rediviva.sav.sk/53i1/14.pdf" target="_blank" >http://www.rediviva.sav.sk/53i1/14.pdf</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Alleviation of extrapyramidal side effects upon switching from risperidone to paliperidone
Original language description
Paliperidone is a new second generation antipsychotic; in terms of pharmacology, it is an active metabolite of risperidone. Compared to risperidone, paliperidone should thus show more stable occupation of dopamine receptors in the brain, which on one thehand may lead to increased antipsychotic efficacy, and on the other hand to reduced incidence of adverse extrapyramidal effects. The case report describes alleviation of Parkinson?s syndrome induced by risperidone by switching to paliperidone in a youngman with a new occurrence of a paranoid schizophrenia episode. Thanks to its clinical efficacy, paliperi- done is ranked among the most successful second generation antipsychotics with reduced extrapyramidal symptomatology
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FL - Psychiatry, sexology
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)